Baxter International Inc. (BAX)
Healthcare · NYQ
Price as at 12 Aug 2026, 04:04 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Baxter International Inc. trades at USD27.61, which is 58% above the USD11.70 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 27 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
BAX dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | USD0.030 | 3 |
| 2025 | USD0.520 | 4 |
| 2024 | USD1.04 | 4 |
| 2023 | USD1.16 | 4 |
| 2022 | USD1.15 | 4 |
| 2021 | USD1.08 | 4 |
| 2020 | USD0.955 | 4 |
| 2019 | USD0.850 | 4 |
| 2018 | USD0.730 | 4 |
| 2017 | USD0.610 | 4 |
| 2016 | USD0.505 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
BAX earnings and analyst estimates
Recommendation mix, 14 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
BAX passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
16 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Richard Pzena, PZENA INVESTMENT MANAGEMENT LLC$1.08B · 3.5% of book
- Dodge & Cox, DODGE & COX$961.88M · 0.5% of book
- Greenhaven Associates, GREENHAVEN ASSOCIATES INC$304.56M · 3.5% of book
- First Pacific Advisors, First Pacific Advisors, LP$112.58M · 1.6% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$41.28M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Baxter International Inc. (BAX) undervalued?
Against our fair value estimate of USD11.70, BAX at USD27.61 is 58% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own BAX?
16 of the institutions we track reported a position in BAX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Does Baxter International Inc. (BAX) pay a dividend?
Yes. Baxter International Inc. yields 0.88% at the current share price. It has paid USD0.040 per share over the trailing twelve months. It has paid a dividend in each of the last 44 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its BAX data?
Fundamentals for BAX come from company filings and exchange data, as listed on NYQ; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 12 Aug 2026, 04:04 UTC and is delayed. Our data quality score for this company is 88/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BAX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.